Michael Gelband’s Ligand Pharmaceuticals LGND Stock Holding History

Michael Gelband’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-13,931	Closed	-$2.47M	–	1821
2025 Q3	$2.47M	Buy	+13,931	New	+$2.07M	0.03%	661
2023 Q4	–	Sell	-27,783	Closed	-$1.67M	–	1792
2023 Q3	$1.67M	Buy	27,783 +6,473	+30%	+$426K	0.02%	737
2023 Q2	$1.54M	Buy	+21,310	New	+$1.6M	0.01%	918
2023 Q1	–	Sell	-18,063	Closed	-$1.21M	–	1968
2022 Q4	$1.21M	Buy	18,063 +9,019	+100%	+$586K	0.02%	866
2022 Q3	$486K	Buy	+9,044	New	+$532K	0.01%	1381
2021 Q2	–	Sell	-3,687	Closed	-$351K	–	2602
2021 Q1	$351K	Sell	3,687 -6,195	-63%	-$586K	0.01%	1567
2020 Q4	$613K	Buy	9,882 +4,573	+86%	+$261K	0.01%	1121
2020 Q3	$316K	Sell	5,309 -10,322	-66%	-$704K	0.01%	1256
2020 Q2	$1.09M	Buy	+15,631	New	+$991K	0.03%	701

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Michael Gelband's LGND Position: Q4 2025 in Review

Michael Gelband sold out of Ligand Pharmaceuticals (LGND) in Q4 2025, closing a stake of 13,931 shares — an estimated $2.47M sold.

Michael Gelband first reported a position in LGND in Q2 2020 and held it in 9 quarters. The position peaked at $2.47M in Q3 2025. 350 funds tracked by Wall St. Rank hold LGND as of Q4 2025.

Michael Gelband reported no remaining Ligand Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Michael Gelband sold 13,931 Ligand Pharmaceuticals shares in Q4 2025, an estimated $2.47M.
Michael Gelband first reported a position in Ligand Pharmaceuticals in Q2 2020 and held it in 9 quarters.
Michael Gelband's Ligand Pharmaceuticals position peaked at $2.47M in Q3 2025.
350 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2025.

Based on ExodusPoint Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.